N-Iodosuccinamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-Iodosuccinamide
• 英文别名: N'-iodobutanediamide
• 化学式: C₄H₇IN₂O₂
• 分子量: 242.016
• InChiKey: KADXVMRYQRCLAH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  72.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-Iodosuccinamide 、 咪唑并[1,2-a]吡啶-6-甲酸甲酯 在 氮气 、 乙酸乙酯 、 sodium hydrogen sulfate 、 Brine 、 magnesium sulfate 作用下， 以 乙腈 为溶剂， 反应 1.0h， 以to give 3-iodo-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester as a pale yellow solid (1.79 g, 95%)的产率得到3-碘咪唑并[1,2-a]吡啶-6-羧酸甲酯
  参考文献：
  名称：

  Retinoid x receptor modulators

  摘要：

  本发明涉及由结构式I表示的化合物及其药学上可接受的盐、溶剂合物和水合物。本发明还涉及制备由结构式I表示的化合物及其药学上可接受的盐、溶剂合物和水合物的医药组合物、使用方法和制备方法。

  公开号：

  US20080090860A1
• 作为试剂：
  描述：

  2,3-二氟苯甲酸 在 N-Iodosuccinamide 、 硫酸 作用下， 反应 5.0h， 以50%的产率得到2,3-二氟-5-碘苯甲酸
  参考文献：
  名称：

  [EN] 3-SPIROPYRIMIDINETRIONE-QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS
  [FR] COMPOSES CHIMIQUES

  摘要：

  公开号：

  WO2009004382A3

文献信息

• 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amide
  申请人：Novartis Corporation

  公开号：US05719141A1

  公开（公告）日：1998-02-17

  Compounds of the formula I ##STR1## in which R.sub.1 is arylamino, N-aryl-N-(lower alkoxy-lower alkyl)-amino, N-aryl-N-aryl-lower alkyl-amino or heterocyclyl bonded via a ring carbon atom, X is a carbonyl or methylene group, R.sub.2 and R.sub.3 independently of one another are hydrogen or lower alkyl or, together with the carbon atom with which they are bonded, are a cycloalkylidene radical, R.sub.4 is hydrogen, lower alkyl, lower alkanoyl or lower alkoxycarbonyl, R.sub.5 is hydroxyl, lower alkanoyloxy or lower alkoxycarbonyloxy, R.sub.6 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkyl-lower alkyl, aryl-lower alkyl or heteroaryl-lower alkyl having 5 to 7 ring atoms in the heteroaryl ring and R.sub.7 is hydrogen or lower alkyl, or R.sub.6 and R.sub.7, together with the carbon atom with which they are bonded, are a cydoalkylidene radical and R.sub.8 denotes an aliphatic, cycloaliphatic-aliphatic or heteroarylaliphatic radical, and their salts can be used as active ingredients for medicaments for treatment of high blood pressure.

  公式I的化合物##STR1##中，其中R.sub.1是芳基氨基，N-芳基-N-(较低烷氧基-较低烷基)-氨基，N-芳基-N-芳基-较低烷基-氨基或通过环碳原子连接的杂环基，X是羰基或亚甲基基团，R.sub.2和R.sub.3彼此独立地是氢或较低烷基，或者与它们连接的碳原子一起是环烷基亚甲基基团，R.sub.4是氢，较低烷基，较低烷酰基或较低烷氧羰基，R.sub.5是羟基，较低烷酰氧基或较低烷氧羰氧基，R.sub.6是氢，较低烷基，较低烯基，较低炔基，环烷基，环烷基-较低烷基，芳基-较低烷基或杂环芳基-较低烷基，在杂环芳基环中有5到7个环原子，R.sub.7是氢或较低烷基，或者R.sub.6和R.sub.7与它们连接的碳原子一起是环烷基亚甲基基团，R.sub.8表示脂肪，环脂肪-脂肪或杂环脂肪基团，它们的盐可用作治疗高血压药物的活性成分。
• Pyrrolo(2,3-d)pyrimidines
  申请人：The Trustees of Princeton University

  公开号：US05248775A1

  公开（公告）日：1993-09-28

  3-Ethynylpyrrolo[2,3-d]pyrimidines are chemical intermediates for antineoplastic N-(acyl)glutamic acid derivatives. A typical embodiment is 3-ethynyl-4-hydroxy-6-pivaloylaminopyrrolo[2,3-d]pyrimidine.

  3-乙炔基吡咯并[2,3-d]嘧啶是抗肿瘤N-(酰基)谷氨酸衍生物的化学中间体。一个典型的实例是3-乙炔基-4-羟基-6-异戊酰胺基吡咯并[2,3-d]嘧啶。
• N-(6-Amino-(pyrrolo(2,3-d)pyrimidin-3-ylacyl) )-glutamic acid derivatives
  申请人：The Trustees of Princeton University

  公开号：US05028608A1

  公开（公告）日：1991-07-02

  N-(Acyl)glutamic acid derivatives in which the acyl group is substituted with 4-hydroxypyrrolo[2,3-d]-pyrimidin-3-yl group are antineoplastic agents. A typical embodiment is N-5-[2-(4-hydroxy-6-aminopyrrolo[2,3-d]pyrimidin-3-yl)ethyl]thien-2-ylcar bonyl}-L-glutamic acid.

  N-(酰基)谷氨酸衍生物中，酰基被4-羟基吡咯并[2,3-d]-嘧啶-3-基团取代时，具有抗肿瘤作用。一个典型的实施例是N-5-[2-(4-羟基-6-氨基吡咯并[2,3-d]嘧啶-3-基)乙基]噻吩-2-基羰基}-L-谷氨酸。
• Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction
  申请人：——

  公开号：US20030083228A1

  公开（公告）日：2003-05-01

  The present invention provides a method of treating female sexual dysfunction, the method comprising the step of administering to a patent, having or at risk of having one or more of the disorders or conditions associated with female sexual dysfunction, a therapeutically effective amount of a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of &agr;-melanocyte stimulating hormone to melanocortin receptors. The present invention also provides a method of identifying a compound that is useful for the treatment or prevention of female sexual dysfunction, the method comprising the steps of: 1) determining if a compound affects the binding of agouti-related protein to melanocortin receptors; 2) determining if a compound affects the binding of &agr;-melanocyte stimulating hormone to melanocortin receptors; and 3) selecting a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not affect the binding of &agr;-melanocyte stimulating hormone to melanocortin receptors.

  本发明提供了一种治疗女性性功能障碍的方法，该方法包括向患有或有可能患有与女性性功能障碍相关的一种或多种疾病或病况的患者施用一种治疗有效量的化合物，该化合物减弱了agouti相关蛋白与黑素皮质素受体的结合，但不影响α-黑素细胞刺激激素与黑素皮质素受体的结合。本发明还提供了一种识别对治疗或预防女性性功能障碍有用的化合物的方法，该方法包括以下步骤：1）确定化合物是否影响agouti相关蛋白与黑素皮质素受体的结合；2）确定化合物是否影响α-黑素细胞刺激激素与黑素皮质素受体的结合；以及3）选择一种减弱agouti相关蛋白与黑素皮质素受体结合的化合物，但不影响α-黑素细胞刺激激素与黑素皮质素受体的结合。
• Methods of treatment and kits comprising a growth hormone secretagogue
  申请人：——

  公开号：US20030105114A1

  公开（公告）日：2003-06-05

  The present invention relates to methods of treating bulimia nervosa, male erectile dysfunction, female sexual dysfunction, thyroid cancer, breast cancer, or ameliorating ischemic nerve or muscle damage. The present invention also relates to kits that can be used in the treatment of bulimia nervosa, male erectile dysfunction, female sexual dysfunction, thyroid cancer, breast cancer, or ameliorating ischemic nerve or muscle damage. The present invention further relates to increasing gastrointestinal motility after surgery and increasing gastrointestinal motility in patients who have been administered an agent that decreases gastrointestinal motility.

  本发明涉及治疗厌食症、男性勃起功能障碍、女性性功能障碍、甲状腺癌、乳腺癌或改善缺血性神经或肌肉损伤的方法。本发明还涉及可用于治疗厌食症、男性勃起功能障碍、女性性功能障碍、甲状腺癌、乳腺癌或改善缺血性神经或肌肉损伤的试剂盒。本发明还涉及术后增加胃肠道蠕动和在接受降低胃肠道蠕动试剂的患者中增加胃肠道蠕动。